Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann
Background Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti‐CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti‐HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti‐HBs) titer have a higher level of protection against reactivation. Aim The purpose of this study was to systematically review the role of anti‐HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis. Methods We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolved HBV infection, defined as HBsAg negative and anti‐HBc positive, which discussed anti‐HBs titer. The search was conducted in PubMed, Embase via Elsevier, Scopus, and Cochrane CENTRAL inclusive July 2025. We evaluated the incidence of HBV reactivation from cohort studies that described anti‐HBs categorically based on anti‐HBs titer: ‘negative’ (titer < 10 iU/L), ‘10–100 iU/L’, or ‘> 100 iU/L’. Meta‐analysis statistics describe the proportion and risk difference for different anti‐HBs levels. Results The overall reactivation rate was 12.6%. There was a significant difference in HBV reactivation depending on titer: anti‐HBs negative 27.3% (51/195) (20.0%–36.0%), titer < 100 iU/L 13.8% (47/379) (8.8%–20.8%), and titer > 100 iU/L 3.5% (8/339) (1.8%–6.9%). Conclusions Those with anti‐HBs titer > 100 iU/L can be considered lower risk for HBV reactivation and may not require antiviral therapy, but monitoring with initiation of antiviral therapy if titer falls below 100 iU/L.
{"title":"Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment","authors":"Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann","doi":"10.1111/apt.70490","DOIUrl":"https://doi.org/10.1111/apt.70490","url":null,"abstract":"Background Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti‐CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti‐HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti‐HBs) titer have a higher level of protection against reactivation. Aim The purpose of this study was to systematically review the role of anti‐HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis. Methods We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolved HBV infection, defined as HBsAg negative and anti‐HBc positive, which discussed anti‐HBs titer. The search was conducted in PubMed, Embase via Elsevier, Scopus, and Cochrane CENTRAL inclusive July 2025. We evaluated the incidence of HBV reactivation from cohort studies that described anti‐HBs categorically based on anti‐HBs titer: ‘negative’ (titer < 10 iU/L), ‘10–100 iU/L’, or ‘> 100 iU/L’. Meta‐analysis statistics describe the proportion and risk difference for different anti‐HBs levels. Results The overall reactivation rate was 12.6%. There was a significant difference in HBV reactivation depending on titer: anti‐HBs negative 27.3% (51/195) (20.0%–36.0%), titer < 100 iU/L 13.8% (47/379) (8.8%–20.8%), and titer > 100 iU/L 3.5% (8/339) (1.8%–6.9%). Conclusions Those with anti‐HBs titer > 100 iU/L can be considered lower risk for HBV reactivation and may not require antiviral therapy, but monitoring with initiation of antiviral therapy if titer falls below 100 iU/L.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"20 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145746670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maria de Brito Nunes,Matthias Knecht,Jonas Schropp,Reiner Wiest,Jaume Bosch,Annalisa Berzigotti
BACKGROUND AND STUDY AIMPost-banding ulcer bleeding (PBUB) is an understudied complication of endoscopic band ligation (EBL) used in the prevention and treatment of oesophageal variceal bleeding (VB). The aim of this study is to investigate the incidence, mortality and risk factors of PBUB.METHODSRetrospective cohort study conducted at the university hospital of Bern (Switzerland). It included patients with cirrhosis and oesophageal varices who underwent prophylactic or urgent EBL for VB between 1 January 2018 and 31 December 2022.RESULTSIn total, 206 patients with cirrhosis, who underwent 630 sessions of EBL, were included. The incidence rate of PBUB was 17.5% (95% CI, 12.7%-23.5%), considering the total number of patients, and 6.8% (95% CI, 5.0%-9.2%) considering the total of EBL procedures. Urgent EBL (SHR: 2.78, 95% CI: 1.29-6.00, p = 0.009) and elevated creatinine (SHR: 1.04, 95% CI: 1.01-1.07, p = 0.024) were independent risk factors for PBUB on multivariate analysis. PBUB required blood product transfusions in 88.1% of events (95% CI, 73.6%-95.5%) and hospitalisation at the intensive care unit in 74.4% of events, with a median hospital stay of 2 days (range: 1-34 days). In patients with PBUB, the short-term mortality during hospitalisation was 19%, and long-term mortality at 52 weeks was 64%.CONCLUSIONSPatients with cirrhosis undergoing urgent EBL or those with elevated creatinine levels are at increased risk of PBUB. Due to the high mortality associated with PBUB, identifying high-risk patients and implementing preventive strategies is essential for improving patient outcomes.
{"title":"Post-Banding Ulcer Bleeding After Endoscopic Ligation: Incidence, Risk Factors and Outcomes in Patients With Cirrhosis.","authors":"Maria de Brito Nunes,Matthias Knecht,Jonas Schropp,Reiner Wiest,Jaume Bosch,Annalisa Berzigotti","doi":"10.1111/apt.70495","DOIUrl":"https://doi.org/10.1111/apt.70495","url":null,"abstract":"BACKGROUND AND STUDY AIMPost-banding ulcer bleeding (PBUB) is an understudied complication of endoscopic band ligation (EBL) used in the prevention and treatment of oesophageal variceal bleeding (VB). The aim of this study is to investigate the incidence, mortality and risk factors of PBUB.METHODSRetrospective cohort study conducted at the university hospital of Bern (Switzerland). It included patients with cirrhosis and oesophageal varices who underwent prophylactic or urgent EBL for VB between 1 January 2018 and 31 December 2022.RESULTSIn total, 206 patients with cirrhosis, who underwent 630 sessions of EBL, were included. The incidence rate of PBUB was 17.5% (95% CI, 12.7%-23.5%), considering the total number of patients, and 6.8% (95% CI, 5.0%-9.2%) considering the total of EBL procedures. Urgent EBL (SHR: 2.78, 95% CI: 1.29-6.00, p = 0.009) and elevated creatinine (SHR: 1.04, 95% CI: 1.01-1.07, p = 0.024) were independent risk factors for PBUB on multivariate analysis. PBUB required blood product transfusions in 88.1% of events (95% CI, 73.6%-95.5%) and hospitalisation at the intensive care unit in 74.4% of events, with a median hospital stay of 2 days (range: 1-34 days). In patients with PBUB, the short-term mortality during hospitalisation was 19%, and long-term mortality at 52 weeks was 64%.CONCLUSIONSPatients with cirrhosis undergoing urgent EBL or those with elevated creatinine levels are at increased risk of PBUB. Due to the high mortality associated with PBUB, identifying high-risk patients and implementing preventive strategies is essential for improving patient outcomes.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"44 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145710838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mattias Mandorfer, Mathias Jachs, Tânia Carvalho, Thomas Reiberger
<p>We would like to thank Drs. Zhu and Li for their editorial [<span>1</span>], which discusses key findings of our study [<span>2</span>] and addresses important points.</p> <p>First, our results do not support the clinical application of ICG-R15 as a non-invasive test (NIT) for clinically significant portal hypertension, as it was outperformed by liver stiffness measurement and ANTICPATE±NASH and did not even come close to the performance of a vibration-controlled transient elastography (VCTE) model that additionally considers spleen stiffness measurement at 100 Hz (SSM; i.e., NICER [<span>3</span>]). Even in a scenario in which elastography was unavailable, VITRO score (von Willebrand factor antigen/platelet count ratio) would be the preferred NIT for diagnosing CSPH in cACLD [<span>4</span>], as the latter showed a numerically higher area under the receiver operating characteristic curve versus ICG-R15. While the limited diagnostic utility of ICG-R15 for CSPH in cACLD seems to come as no real surprise for Drs. Zhu and Li [<span>1</span>], it is important to mention that previous work on ICG-R15 determined via venous blood sampling drew a more optimistic picture. Furthermore, a bicentric study from China [<span>5</span>] became available after the publication of our work, in which ICG-R15 by PDD showed an AUROC for CSPH > 0.85 in both the derivation and validation cohorts. However, the prevalence of CSPH was considerably lower (42%–46%) than in our study (62%) [<span>2</span>] and more than one fourth of patients did not have cACLD as defined by LSM ≥ 10 kPa, suggesting the inclusion of less advanced patients who are easier to classify [<span>6</span>]. All things considered, LSM by VCTE as well as platelet count remain the mainstay of the non-invasive diagnosis of CSPH and may be better complemented by SSM [<span>3</span>] or VITRO [<span>7</span>], rather than ICG-R15 by PDD.</p> <p>Importantly, our results emphasise that for predicting first hepatic decompensation, hepatic (dys)function should not be neglected, as it is the second key prognostic indicator [<span>8</span>] besides CSPH evaluated by minimally invasive [<span>9</span>] or non-invasive methods [<span>6</span>]. However, whether ICG-R15 by PDD adds clinically meaningful information to that provided by simple tests of hepatic (dys)function such as serum albumin remains to be determined [<span>10</span>], as the low number of events in the cACLD group precluded multivariate analyses.</p> <p>Second, we would like to point out that all assessments in our study were performed in clinically stable outpatients, indicating that ICG-R15 but also other parameters reflect an individual patient's steady state rather than fluctuations, as observed in patients with acute decompensation or acute-on-chronic liver failure. This is an important aspect, as the purpose of the study was not to predict the course of a hospitalisation due to acute decompensation, but rather to investigate whether I
{"title":"Editorial: ICG-R15 by PDD—A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease. Authors' Reply","authors":"Mattias Mandorfer, Mathias Jachs, Tânia Carvalho, Thomas Reiberger","doi":"10.1111/apt.70493","DOIUrl":"https://doi.org/10.1111/apt.70493","url":null,"abstract":"<p>We would like to thank Drs. Zhu and Li for their editorial [<span>1</span>], which discusses key findings of our study [<span>2</span>] and addresses important points.</p>\u0000<p>First, our results do not support the clinical application of ICG-R15 as a non-invasive test (NIT) for clinically significant portal hypertension, as it was outperformed by liver stiffness measurement and ANTICPATE±NASH and did not even come close to the performance of a vibration-controlled transient elastography (VCTE) model that additionally considers spleen stiffness measurement at 100 Hz (SSM; i.e., NICER [<span>3</span>]). Even in a scenario in which elastography was unavailable, VITRO score (von Willebrand factor antigen/platelet count ratio) would be the preferred NIT for diagnosing CSPH in cACLD [<span>4</span>], as the latter showed a numerically higher area under the receiver operating characteristic curve versus ICG-R15. While the limited diagnostic utility of ICG-R15 for CSPH in cACLD seems to come as no real surprise for Drs. Zhu and Li [<span>1</span>], it is important to mention that previous work on ICG-R15 determined via venous blood sampling drew a more optimistic picture. Furthermore, a bicentric study from China [<span>5</span>] became available after the publication of our work, in which ICG-R15 by PDD showed an AUROC for CSPH > 0.85 in both the derivation and validation cohorts. However, the prevalence of CSPH was considerably lower (42%–46%) than in our study (62%) [<span>2</span>] and more than one fourth of patients did not have cACLD as defined by LSM ≥ 10 kPa, suggesting the inclusion of less advanced patients who are easier to classify [<span>6</span>]. All things considered, LSM by VCTE as well as platelet count remain the mainstay of the non-invasive diagnosis of CSPH and may be better complemented by SSM [<span>3</span>] or VITRO [<span>7</span>], rather than ICG-R15 by PDD.</p>\u0000<p>Importantly, our results emphasise that for predicting first hepatic decompensation, hepatic (dys)function should not be neglected, as it is the second key prognostic indicator [<span>8</span>] besides CSPH evaluated by minimally invasive [<span>9</span>] or non-invasive methods [<span>6</span>]. However, whether ICG-R15 by PDD adds clinically meaningful information to that provided by simple tests of hepatic (dys)function such as serum albumin remains to be determined [<span>10</span>], as the low number of events in the cACLD group precluded multivariate analyses.</p>\u0000<p>Second, we would like to point out that all assessments in our study were performed in clinically stable outpatients, indicating that ICG-R15 but also other parameters reflect an individual patient's steady state rather than fluctuations, as observed in patients with acute decompensation or acute-on-chronic liver failure. This is an important aspect, as the purpose of the study was not to predict the course of a hospitalisation due to acute decompensation, but rather to investigate whether I","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"29 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145718450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Editorial: Beyond DNA Suppression: HBV RNA as a Predictor of Hepatocarcinogenesis.","authors":"Toshifumi Tada","doi":"10.1111/apt.70497","DOIUrl":"https://doi.org/10.1111/apt.70497","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"31 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145710836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Our most recent 2-year impact factor of 6.7 keeps AP&T in 18th position among 147 journals in our field. We congratulate the authors of the 10 papers published in 2024 that were most highly cited in 2025 [1-10], and of the 10 most frequently downloaded papers between October 2024 and September 2025 [11-20]. As expected, steatotic liver disease and IBD continue to be highly important topics for AP&T.
Excluding editorials and letters, we received 2,020 new submissions between January and September 2025, and ultimately accepted 153 (7.6%). Decisions on individual submissions are made objectively and are based on quality and likely relevance to the readership. We strive to maintain a balance between hepatology and ‘luminal’ gastroenterology. For some papers we are unable to accept, we offer transfer—as appropriate—to Neurogastroenterology and Motility, Basic & Clinical Pharmacology & Toxicology, or Pharmacology Research and Perspectives.
During 2025, Cynthia Seow stepped down from her position as Associate Editor and will be replaced by Tim Card (University of Nottingham, UK). Alex Ford also stepped down at the end of 2025 after 14 years with the journal. Alex will be replaced by Chris Black (University of Leeds, UK). We thank Cynthia and Alex for their service and look forward to working with Tim and Chris. We congratulate Alex on his new position as Deputy Editor-in-Chief of Gut.
One change made in 2025 was the discontinuation of the Research Communication option. In 2026, submissions to AP&T, as well as the peer-review process, are now handled through our publisher's Research Exchange (ReX) system. Doubtless, there will be a learning curve but we hope that this will streamline the submission and review process and provide yet more safeguards against such issues as plagiarism, image manipulation and other forms of academic misconduct.
Please continue to consider AP&T for your original research and review articles in digestive and liver disease. Authors with a proposal for a review article may contact us in advance to discuss its content and scope. While we cannot accept many of the submissions we receive, we will provide a scrupulously fair and transparent review process and a rapid decision. In fact, AP&T continues to have the shortest decision times among journals in our field.
{"title":"A Message From the Editors","authors":"Colin W. Howden, Rohit Loomba","doi":"10.1111/apt.70454","DOIUrl":"https://doi.org/10.1111/apt.70454","url":null,"abstract":"<p>Welcome to the first edition of <i>AP&T</i> for 2026.</p><p>Our most recent 2-year impact factor of 6.7 keeps <i>AP&T</i> in 18th position among 147 journals in our field. We congratulate the authors of the 10 papers published in 2024 that were most highly cited in 2025 [<span>1-10</span>], and of the 10 most frequently downloaded papers between October 2024 and September 2025 [<span>11-20</span>]. As expected, steatotic liver disease and IBD continue to be highly important topics for <i>AP&T</i>.</p><p>Excluding editorials and letters, we received 2,020 new submissions between January and September 2025, and ultimately accepted 153 (7.6%). Decisions on individual submissions are made objectively and are based on quality and likely relevance to the readership. We strive to maintain a balance between hepatology and ‘luminal’ gastroenterology. For some papers we are unable to accept, we offer transfer—as appropriate—to <i>Neurogastroenterology and Motility</i>, <i>Basic & Clinical Pharmacology & Toxicology</i>, or <i>Pharmacology Research and Perspectives</i>.</p><p>During 2025, Cynthia Seow stepped down from her position as Associate Editor and will be replaced by Tim Card (University of Nottingham, UK). Alex Ford also stepped down at the end of 2025 after 14 years with the journal. Alex will be replaced by Chris Black (University of Leeds, UK). We thank Cynthia and Alex for their service and look forward to working with Tim and Chris. We congratulate Alex on his new position as Deputy Editor-in-Chief of <i>Gut</i>.</p><p>One change made in 2025 was the discontinuation of the Research Communication option. In 2026, submissions to <i>AP&T</i>, as well as the peer-review process, are now handled through our publisher's Research Exchange (ReX) system. Doubtless, there will be a learning curve but we hope that this will streamline the submission and review process and provide yet more safeguards against such issues as plagiarism, image manipulation and other forms of academic misconduct.</p><p>Please continue to consider <i>AP&T</i> for your original research and review articles in digestive and liver disease. Authors with a proposal for a review article may contact us in advance to discuss its content and scope. While we cannot accept many of the submissions we receive, we will provide a scrupulously fair and transparent review process and a rapid decision. In fact, <i>AP&T</i> continues to have the shortest decision times among journals in our field.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"63 1","pages":"4-5"},"PeriodicalIF":6.7,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70454","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p> <b> <i>Professor C. W. Howden, Editor</i> </b> </p><p>Professor Howden is a consultant/speaker for Phathom Pharmaceuticals, consultant/speaker for RedHill Biopharma, consultant/speaker for Meridian Diagnostics, consultant for Sebela/Braintree and consultant for ISOThrive. He has stock options in EndoStim.</p><p> <b> <i>Professor R. Loomba, Editor</i> </b> </p><p>Professor Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. He has stock options in Sagimet biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. He is also the co-founder of LipoNexus Inc.</p><p> <b> <i>Professor G. M. Dusheiko, Associate Editor</i> </b> </p><p>Professor Dusheiko serves on independent data safety monitoring boards for Aligos, Arbutus, Glaxo Smith Kline, Janssen and Gilead. In the past two years, he has received honoraria from Arbutus, Antios, Aligos and Gilead Sciences, and he serves as an advisor to the National Medical Research Council, Singapore; the TherVacB Consortium (European Horizon Grant); and the A-Tango Consortium (EUH2020 grant).</p><p> <b> <i>Professor G. L.-H. Wong, Associate Editor</i> </b> </p><p>Professor Wong has served as an advisory committee member for AstraZeneca, Barinthus Biotherapeutics, Gilead Sciences, GlaxoSmithKline, Janssen and Virion; has served as a speaker for Abbott, AbbVie, Ascletis Pharmaceuticals, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, GlaxoSmithKline, Janssen and Roche; and has received research grants from Gilead Sciences.</p><p> <b> <i>Professor R. B. Gearry, Associate Editor</i> </b> </p><p>Professor Gearry is, or has been, a member of advisory boards for AbbVie, Janssen, Schering-Plough, Zespri, Baxter and Celltrion. He has received honoraria or travel grants from AbbVie, Janssen, Schering Plough, Zespri, Ferring and Celltrion. He has received research grants for investigator-initiated studies from AbbVie, Janssen, Goodman-Fielder, Comvita and Zespri.</p><p> <b> <i>Dr. S. Subramanian, Associate Editor</i> </b> </p><p>Dr. Subramanian is/has been on the speaker bureau for Abbvie, Bristol-Myers Squibb, Celltrio
{"title":"AP&T: Editors' Declarations of Interest","authors":"","doi":"10.1111/apt.70468","DOIUrl":"https://doi.org/10.1111/apt.70468","url":null,"abstract":"<p>\u0000 <b>\u0000 <i>Professor C. W. Howden, Editor</i>\u0000 </b>\u0000 </p><p>Professor Howden is a consultant/speaker for Phathom Pharmaceuticals, consultant/speaker for RedHill Biopharma, consultant/speaker for Meridian Diagnostics, consultant for Sebela/Braintree and consultant for ISOThrive. He has stock options in EndoStim.</p><p>\u0000 <b>\u0000 <i>Professor R. Loomba, Editor</i>\u0000 </b>\u0000 </p><p>Professor Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. He has stock options in Sagimet biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. He is also the co-founder of LipoNexus Inc.</p><p>\u0000 <b>\u0000 <i>Professor G. M. Dusheiko, Associate Editor</i>\u0000 </b>\u0000 </p><p>Professor Dusheiko serves on independent data safety monitoring boards for Aligos, Arbutus, Glaxo Smith Kline, Janssen and Gilead. In the past two years, he has received honoraria from Arbutus, Antios, Aligos and Gilead Sciences, and he serves as an advisor to the National Medical Research Council, Singapore; the TherVacB Consortium (European Horizon Grant); and the A-Tango Consortium (EUH2020 grant).</p><p>\u0000 <b>\u0000 <i>Professor G. L.-H. Wong, Associate Editor</i>\u0000 </b>\u0000 </p><p>Professor Wong has served as an advisory committee member for AstraZeneca, Barinthus Biotherapeutics, Gilead Sciences, GlaxoSmithKline, Janssen and Virion; has served as a speaker for Abbott, AbbVie, Ascletis Pharmaceuticals, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, GlaxoSmithKline, Janssen and Roche; and has received research grants from Gilead Sciences.</p><p>\u0000 <b>\u0000 <i>Professor R. B. Gearry, Associate Editor</i>\u0000 </b>\u0000 </p><p>Professor Gearry is, or has been, a member of advisory boards for AbbVie, Janssen, Schering-Plough, Zespri, Baxter and Celltrion. He has received honoraria or travel grants from AbbVie, Janssen, Schering Plough, Zespri, Ferring and Celltrion. He has received research grants for investigator-initiated studies from AbbVie, Janssen, Goodman-Fielder, Comvita and Zespri.</p><p>\u0000 <b>\u0000 <i>Dr. S. Subramanian, Associate Editor</i>\u0000 </b>\u0000 </p><p>Dr. Subramanian is/has been on the speaker bureau for Abbvie, Bristol-Myers Squibb, Celltrio","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"63 1","pages":"6-7"},"PeriodicalIF":6.7,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70468","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Editorial: MetALD and Risk of Gastrointestinal Cancer-What Can We Learn From Japan? Authors' Reply.","authors":"Nobuharu Tamaki,Takefumi Kimura,Shun-Ichi Wakabayashi,Masayuki Kurosaki","doi":"10.1111/apt.70489","DOIUrl":"https://doi.org/10.1111/apt.70489","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"372 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francisco Idalsoaga,Luis Antonio Díaz,Stephen Hoang,Mohammad Qasim Khan,Juan Pablo Arab
{"title":"Letter on 'Meta-Analysis: Mortality Trends and Risk Factors in Severe Alcohol-Associated Hepatitis'-Authors' Reply.","authors":"Francisco Idalsoaga,Luis Antonio Díaz,Stephen Hoang,Mohammad Qasim Khan,Juan Pablo Arab","doi":"10.1111/apt.70488","DOIUrl":"https://doi.org/10.1111/apt.70488","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"6 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Editorial: MetALD and Risk of Gastrointestinal Cancer-What Can We Learn From Japan?","authors":"Hannes Hagström,Ying Shang","doi":"10.1111/apt.70477","DOIUrl":"https://doi.org/10.1111/apt.70477","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"2 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：